Last update: Dec. 1, 2004

Pizotifen

Low Risk for breastfeeding


Moderately safe. Probably compatible.
Mild risk possible. Follow up recommended.
Read the Comment.

It is a first generation antihistaminic and piperidine drug with a moderately sedative effect. Minimally secreted into breast milk. Indicated for anorexia (Cyproheptadine is safer) and long-term prophylaxis of migraine (Propranolol or Valproate are considered to be safer drugs)

Alternatives

Suggestions made at e-lactancia are done by APILAM´s pediatricians and pharmacists, and are based on updated scientific publications.
It is not intended to replace the relationship you have with your doctor but to compound it.

Jose Maria Paricio, Founder & President of APILAM/e-Lactancia

Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.

Thank you for helping to protect and promote breastfeeding.

José María Paricio, founder of e-lactancia.

Other names

Pizotifen is also known as


Group

Pizotifen belongs to this group or family:

Tradenames

Main tradenames from several countries containing Pizotifen in its composition:

Pharmacokinetics

Variable Value Unit
Oral Bioavail. Alta - Hig %
Molecular weight 295 daltons
Protein Binding 90 %
Tmax 5 hours
T1/2 23 hours

References

  1. Davanzo R, Bua J, Paloni G, Facchina G. Breastfeeding and migraine drugs. Eur J Clin Pharmacol. 2014 Abstract

Total visits

3,236

Help us improve this entry

How to cite this entry

Do you need more information or did not found what you were looking for?

   Write to us at elactancia.org@gmail.com

e-lactancia is a resource recommended by La Liga de la Leche de México from Mexico

Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM